Developing precision medicines for kidney diseases
Chinook is a clinical-stage biopharmaceutical company discovering, developing and commercializing precision medicines for rare, severe chronic kidney diseases.
News & HIGHLIGHTs
October 5, 2020
Chinook Therapeutics Closes Merger with Aduro Biotech and Completes $115 Million Private Placement Financing
October 5, 2020
Download the latest Chinook Corporate Presentation
Atrasentan Update
We plan to initiate a Phase 3 clinical trial (ALIGN) of atrasentan in early 2021 for biomarker-selected patients with IgA Nephropathy at high risk for progressive kidney function loss.
Pipeline
Advancing a pipeline of precision medicines for kidney diseases.
Our lead pipeline candidates target rare, severe kidney disorders with few currently approved therapies.
